FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Precigen Reports Fourth Quarter and Full Year 2020 Financial Results
- Company successfully accomplished anticipated 2020 clinical milestones despite challenges due to the ongoing pandemic -
- Strengthened balance sheet with successful public offering while streamlining operations and reducing operating costs -
- Initial data readouts from PRGN-3005 and PRGN-3006 UltraCAR-T® clinical trials demonstrated encouraging expansion, persistence and clinical activity -
- A PRGN-3006 UltraCAR-T patient achieved complete remission with incomplete hematologic recovery (CRi) per ELN criteria -
- Initiated first AdenoVerse™ immunotherapy clinical trial for PRGN-2009 in HPV-associated solid tumors -
- Interim data for AG019 ActoBiotics™ in T1D indicate encouraging trends in C-peptide levels and ability to induce antigen-specific immune modulation following only one treatment cycle of oral AG019 as monotherapy or combination -
This article has been reviewed and updated as of April 13, 2021.
On April 13, 2021, the U.S. Food and Drug Administration (FDA) and U.S. Centers for Disease Control and Prevention (CDC) asked states to temporarily halt using the Johnson & Johnson’s COVID-19 vaccine “out of an abundance of caution” after receiving six reports of a rare and severe type of blood clot forming in individuals after receiving the vaccine. CreakyJoints is monitoring this news closely and will keep readers updated as more information is released.
Now that that the U.S. Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for the Johnson & Johnson COVID-19 vaccine, people who take immunosuppressant medications, are immunocompromised, or who have autoimmune conditions have questions and concerns about what this development means for them.
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
News provided by
Share this article
SAN DIEGO, Feb. 25, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. Over the last several months we achieved key clinical milestones, which provided the momentum for our successful raise of over $100 million. Together, these events have enabled us to accelerate the execution of our clinical programs and expand our pipeline to other relevant cancer indications, said Dr. Mark Erlander, chief executive officer of Cardiff Oncology. Data from our lead KRAS-mutated metastatic color
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.